论文部分内容阅读
目的观察益肾I方对多囊卵巢综合征-代谢综合征(PCOS-MetS)大鼠胰岛素抵抗(IR)、血脂异常及氧化应激-自由基损伤的作用。方法采用十一酸睾酮加绒毛膜促性腺激素(HCG)建立PCOS-MetS大鼠模型,连续口服给予二甲双胍或不同剂量的益肾I方4周,观察大鼠体质量、血清肿瘤坏死因子-α(TNF-α)、睾酮(T)、丙二醛(MDA)、一氧化氮(NO)、胆固醇(TC)、甘油三酯(TG),低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FBG)和口服葡萄糖后2h血糖(OGTT-2hBG)和胰岛素含量以及超氧化物歧化酶(SOD)和诱导型一氧化氮合酶(iNOS)-一氧化氮合酶(NOS)活性,并计算胰岛素敏感指数(ISI)的变化。结果PCOS-MetS大鼠体质量明显增加,与空白对照组比较,差异有统计学意义(P<0.01);血清TNF-α、T、MDA、NO、TG、TC、LDL-C、FBG、OGTT-2hBG和胰岛素水平以及iNOS-NOS活性,均明显升高,而HDL-C含量、SOD活性和ISI则显著降低,与空白对照组比较,差异有统计学意义(P<0.01);二甲双胍和益肾I方高和中2个剂量均能不同程度地改善PCOS-MetS大鼠体质量增加、高雄激素血症、高血糖血症、高脂血症、高胰岛素血症和IR等病理生理改变(P<0.01或P<0.05),以及增强抗氧化酶SOD活性,抑制NOS和iNOS活性,降低MDA和NO水平(P<0.01或P<0.05)。结论益肾I方能改善PCOS-MetS大鼠胰岛素敏感性,对抗高雄激素血症和脂质代谢异常以及氧化应激-自由基损伤,并提高抗氧化能力。
Objective To observe the effect of Yishen I prescription on insulin resistance (IR), dyslipidemia and oxidative stress-free radical injury in rats with polycystic ovary syndrome-metabolic syndrome (PCOS-MetS). Methods PCOS-MetS rat model was established by testosterone undecanoate plus human chorionic gonadotropin (HCG). Metformin or different doses of Yishen I were given orally continuously for 4 weeks. The body weight and serum tumor necrosis factor-α were observed. (TNF-α), testosterone (T), malondialdehyde (MDA), nitric oxide (NO), cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density Lipoprotein cholesterol (HDL-C), fasting plasma glucose (FBG), and 2-hour post-glucose glucose (OGTT-2hBG) and insulin levels, as well as superoxide dismutase (SOD) and inducible nitric oxide synthase (iNOS)- Nitric oxide synthase (NOS) activity, and changes in insulin sensitivity index (ISI) were calculated. Results The body weight of PCOS-MetS rats increased significantly compared with the blank control group (P<0.01); Serum TNF-α, T, MDA, NO, TG, TC, LDL-C, FBG, OGTT -2hBG and insulin levels as well as iNOS-NOS activity were significantly increased, while HDL-C content, SOD activity, and ISI were significantly lower, compared with the blank control group, the difference was statistically significant (P <0.01); metformin and benefits Both high and middle doses of Kidney I can improve the pathophysiological changes of body weight, hyperandrogenism, hyperglycemia, hyperlipidemia, hyperinsulinemia and IR in PCOS-MetS rats to varying degrees ( P<0.01 or P<0.05), as well as enhanced antioxidant enzyme activity of SOD, inhibition of NOS and iNOS activity and reduction of MDA and NO levels (P<0.01 or P<0.05). Conclusion Yishen I can improve the insulin sensitivity of PCOS-MetS rats, against hyperandrogenism and abnormal lipid metabolism, and oxidative stress-free radical damage, and improve the antioxidant capacity.